FindTrial
Sign In

Chemotherapeutic Agent

DRUG4 trials

Sponsors

Fudan University, Fuzhou General Hospital, Day One Biopharmaceuticals, Inc., Jiangsu Cancer Institute & Hospital

Conditions

Gastric or Gastroesophageal Junction AdenocarcinomaLow-grade GliomaNon-small Cell Lung CancerPediatric Low-grade GliomaRapidly Accelerated Fibrosarcoma (RAF) Altered GliomaTriple Negative Breast Cancer

Phase 2

Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruitingNCT07408609
Jiangsu Cancer Institute & HospitalGastric or Gastroesophageal Junction Adenocarcinoma
Start: 2026-02-26End: 2031-02-20Target: 114Updated: 2026-02-13

Phase 3

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
RecruitingNCT05566795
Day One Biopharmaceuticals, Inc.Low-grade Glioma, Pediatric Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma
Start: 2023-02-27End: 2031-06-01Target: 400Updated: 2026-03-02

Phase 4

Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer
NCT03799679
Fudan UniversityTriple Negative Breast Cancer
Start: 2018-11-26End: 2020-02-01Target: 60Updated: 2019-01-10

Unknown Phase

ctDNA as a Biomarker for Treatment in Advanced NSCLC
NCT05486988
Fuzhou General HospitalNon-small Cell Lung Cancer
Start: 2022-07-31End: 2025-06-30Target: 500Updated: 2022-08-04

Related Papers

LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration
BMC Cancer2024-01-3048 citations
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial.
2023-11-17102 citations
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study.
Journal of Clinical Oncology2023-06-0113 citations
LOGGIC/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating <i>RAF</i> alteration.
Journal of Clinical Oncology2023-06-014 citations
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
2023-05-2327 citations
<i>Nab</i>-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
The Oncologist2022-11-257 citations